NEW YORK, March 5, 2015 (GLOBE NEWSWIRE) -- New York-based AXIM Biotechnologies, Inc. (OTC:AXIM) proudly presented its line of the world's first oral care and cosmetic products that include cannabigerol (CBG) during a recent news conference. The presentation capped a week of events including AXIM Biotech's participation in the Cannabis Economy Global Conference in New York City.
Photos accompanying this release are available at
http://www.globenewswire.com/newsroom/prs/?pkgid=31191
http://www.globenewswire.com/newsroom/prs/?pkgid=31192
http://www.globenewswire.com/newsroom/prs/?pkgid=31193
The focus: Retail-ready CBG cannabis products with global availability.
The announcement caught the attention of many media outlets including FOX Business, CRAINS New York, MainStreet.com, MJ Freeway and more.
"In 2015, these products will come to market and provide cutting edge health and beauty options for consumers," said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer for AXIM Biotechnologies. "The toothpaste market is a $20 billion industry, and the cosmetics market is a $420 billion industry. So we do not consider other brands as our competitors. There's plenty of room to go around."
The following is a list of several ground-breaking, retail-ready CBG hemp cannabis-infused products from AXIM Biotech:
- Toothpaste
- Mouthwash
- Dentifrice
- Oral Gel (for minor cuts and sores)
- Diaper Rash Cream
- Moisturizers
- Lotions
- Lip Balm
- Shampoo
- Conditioner
- Body Wash
- Day Cream
- Night Cream
- Eye Cream
All of the products unveiled by AXIM Biotech are tested and free of heavy metals, pesticides, fungi or bacteria.
"We use only pharmaceutical grade cannabinoid products," Anastassov said. "There are no irritants. Everything is 100% natural."
Complete use of the industrial hemp plant is at the core of the Company's business plan, which aims to use the natural plant to benefit human health, while providing clean alternative energy and delivering many other innovative applications. By focusing efforts on unique proprietary delivery mechanisms for the introduction of cannabinoids (e.g. CBD, CBG, CBN), AXIM Biotechnologies has charted a course and is actively developing solutions for conditions for which there currently are no effective treatments.
AXIM Biotech also creates strategic partnerships and acquisitions, allowing ongoing research and development in the areas of functional foods, nutraceuticals, pharmaceuticals, cosmetics, and clean energy – all derived from the industrial hemp plant.
For more information, visit AXIM Biotech's website.
To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@CMWmedia.com or call 858-380-5478.
About AXIM:
AXIM Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
The photos are also available at Newscom, www.newscom.com, and via AP PhotoExpress.